ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive lymphoma with no approved treatment in the U.S.1 OSAKA, Japan, March 25, 2024 /PRNewswire/ — ONO Pharmaceuticals, Co., Ltd. today announced it has completed target patient enrollment of the first arm (Part A) of the…